ES2190350B1 - Composicion de vacuna frente a la brucelosis que comprende microparticulas de poli (e-caprolactona) como adyuvante. - Google Patents

Composicion de vacuna frente a la brucelosis que comprende microparticulas de poli (e-caprolactona) como adyuvante.

Info

Publication number
ES2190350B1
ES2190350B1 ES200101801A ES200101801A ES2190350B1 ES 2190350 B1 ES2190350 B1 ES 2190350B1 ES 200101801 A ES200101801 A ES 200101801A ES 200101801 A ES200101801 A ES 200101801A ES 2190350 B1 ES2190350 B1 ES 2190350B1
Authority
ES
Spain
Prior art keywords
poly
caprolactone
microparticles
brucelosis
assistant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES200101801A
Other languages
English (en)
Other versions
ES2190350A1 (es
Inventor
Carlos Gamazo De La Rasilla
Juan Manuel Irache Garreta
Jose Blasco Martinez
Maria Del Mar Goñi Leza
Maria Isabel Murillo Martin
Maria Jesus Grillo Dolset
Clara Marin Alcala
Monserrat Barberan Pelegrin
Judith Reñe Gonzalez
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GRILLO DOLSET M JESUS
Instituto Cientifico y Tecnologico de Navarra SA
Original Assignee
GRILLO DOLSET M JESUS
Instituto Cientifico y Tecnologico de Navarra SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GRILLO DOLSET M JESUS, Instituto Cientifico y Tecnologico de Navarra SA filed Critical GRILLO DOLSET M JESUS
Priority to ES200101801A priority Critical patent/ES2190350B1/es
Priority to AU2002365205A priority patent/AU2002365205A1/en
Priority to PCT/ES2002/000367 priority patent/WO2003059383A1/es
Priority to ARP020102898A priority patent/AR034950A1/es
Publication of ES2190350A1 publication Critical patent/ES2190350A1/es
Application granted granted Critical
Publication of ES2190350B1 publication Critical patent/ES2190350B1/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/098—Brucella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La composición de vacuna comprende una sustancia antigénicamente activa frente a Brucella spp. y un adyuvante que comprende micropartículas de poli(e-caprolactona) que encapsulan a dicha sustancia antigénicamente activa frente a Brucella spp. en una realización particular, la vacuna es una vacuna subcelular que comprende antígenos de membrana (complejos de lipopolisacárido con proteínas de membrana externa).
ES200101801A 2001-07-31 2001-07-31 Composicion de vacuna frente a la brucelosis que comprende microparticulas de poli (e-caprolactona) como adyuvante. Expired - Lifetime ES2190350B1 (es)

Priority Applications (4)

Application Number Priority Date Filing Date Title
ES200101801A ES2190350B1 (es) 2001-07-31 2001-07-31 Composicion de vacuna frente a la brucelosis que comprende microparticulas de poli (e-caprolactona) como adyuvante.
AU2002365205A AU2002365205A1 (en) 2001-07-31 2002-07-23 Brucellosis vaccine composition comprising poly($g(e)-caprolactone) microparticles as an adjuvant
PCT/ES2002/000367 WO2003059383A1 (es) 2001-07-31 2002-07-23 COMPOSICÍON DE VACUNA FRENTE A LA BRUCELOSIS QUE COMPRENDE MICROPARTÍCULAS DE POLI(ϵ-CAPROLACTONA) COMO ADYUVANTE
ARP020102898A AR034950A1 (es) 2001-07-31 2002-07-31 Composicion de vacuna frente a la brucelosis que comprende microparticulas de poli(e-caprolactona) como adyuvante

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200101801A ES2190350B1 (es) 2001-07-31 2001-07-31 Composicion de vacuna frente a la brucelosis que comprende microparticulas de poli (e-caprolactona) como adyuvante.

Publications (2)

Publication Number Publication Date
ES2190350A1 ES2190350A1 (es) 2003-07-16
ES2190350B1 true ES2190350B1 (es) 2005-01-01

Family

ID=8498592

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200101801A Expired - Lifetime ES2190350B1 (es) 2001-07-31 2001-07-31 Composicion de vacuna frente a la brucelosis que comprende microparticulas de poli (e-caprolactona) como adyuvante.

Country Status (4)

Country Link
AR (1) AR034950A1 (es)
AU (1) AU2002365205A1 (es)
ES (1) ES2190350B1 (es)
WO (1) WO2003059383A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2327375B1 (es) 2007-11-14 2010-08-05 Universidad Del Pais Vasco Empleo de microparticulas para su uso como vacunas y la liberacion de moleculas biologicamente activas.
AR073907A1 (es) 2009-10-19 2010-12-09 Consejo Nac Invest Cient Tec Adyuvante para vacunas, que comprende un polipeptido no lipidado de la membrana externa (omp) de bacterias, vacunas que lo comprenden y usos

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061062A1 (en) * 1998-05-29 1999-12-02 Massachusetts Institute Of Technology Cyclodextrin complexes

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GAMAZO C. et al., "Comparative Analisis of Proteins Extracted by Hot Saline or Released Spontaneously into Outer Membrane Blebs from Field Strains of Brucella oris and Brucella melitensis". 1989. INFECT. and IMMUN., Vol. 57 (5). Páginas 1419-1426. *
MURILLON et al., "A Brucella oris antigenic complex bearing poli-episolon-caprolactone microparticles confer protection against experimental brucellosis in mice". VACCINE, Vol. (19). 20.07.2001. Páginas 4099-4106. *

Also Published As

Publication number Publication date
WO2003059383A1 (es) 2003-07-24
ES2190350A1 (es) 2003-07-16
AR034950A1 (es) 2004-03-24
AU2002365205A1 (en) 2003-07-30

Similar Documents

Publication Publication Date Title
ATE270707T1 (de) Entepneumovirus und entsprechendes impfstoff
DK1094837T3 (da) Porcin circovirus og parvovirusvaccine
BR0210005B1 (pt) Polímero, processo para o preparo do mesmo e estrutura absorvente.
ID27788A (id) Peptida-peptida antigen tumor yang diperoleh dari siklofilin b
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
DE69733652D1 (de) Eigenschaften von poly(amidoamine) dendrimeren als adjuvantien
DE60238131D1 (de) Pharmazeutische zubereitungen enthaltend kolloidales siliciumdioxid
BR0313870A (pt) Aparelho e métodos de serviços da rede
NO20023935D0 (no) Ny, ikke-antigen, mucosal adjuvantformulering som modulerer effektene av substanser, inkludert vaksineantigener, i kontakt medmucosale kroppsoverflater
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
NO991524L (no) Vaksiner
NO20023829D0 (no) Proteosom influensavaksine
ES2196620T3 (es) Formulacion de liberacion prolongada que contiene venlafaxina.
ITTO20010459A0 (it) Dispositivo di trattenimento standardizzato per cartellini, cappellini e oggetti simili.
ATE314084T1 (de) Kahalalid f formulierung
ID20581A (id) Antigen rotavirus, vaksin dan agen diagnostik untuk infeksi rotavirus, serta metode untuk menghasilkan antigen
ES2181168T3 (es) Mezclas solidas a base de sulfonilureas y adyuvantes.
NO972219D0 (no) Immunogenpreparater
ES2177509T3 (es) Empleo de anticuerpos para la vacunacion contra el cancer.
ES2190350B1 (es) Composicion de vacuna frente a la brucelosis que comprende microparticulas de poli (e-caprolactona) como adyuvante.
SE9604581D0 (sv) An agent against cancer and virus infections
DE60141297D1 (de) Gegen das menschliche bst2 antigen gerichteter monoklonaler antikörper
AU2001242190A1 (en) Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
CO5660272A2 (es) Vacunas bovinas con adyuvantes
BR0009077A (pt) Antìgenos de tuberculose e métodos de uso dos mesmos

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20030716

Kind code of ref document: A1

FG2A Definitive protection

Ref document number: 2190350B1

Country of ref document: ES

FA2A Application withdrawn

Effective date: 20051004